Bio-Techne Announces Conference Call for Q1 Fiscal Results

Author: Evelyn Baker Updated: 10-15-2025 07:14 AM

Bio-Techne Corporation to Host Financial Results Conference Call

Bio-Techne Corporation (NASDAQ: TECH) is preparing to engage with its stakeholders through a conference call scheduled for an upcoming date. This call aims to discuss the financial performance during the first quarter of fiscal 2026, providing an opportunity for the management team to share insights and analyses.

Details of the Upcoming Conference Call

The management has confirmed that the conference call will take place at 8:00 a.m. CST. Participants can dial in using the numbers provided, or they may choose to join via the online webcast platform set up by the company. The specific phone numbers for dial-in access are 1-800-274-8461 for domestic callers and 1-203-518-9814 for international participants.

Conference Call ID and Webcast Access

To access the call, attendees will need the Conference ID, which is TECHQ1. Additionally, a webcast will be available for those who prefer to join online. The link to the webcast will be made available prior to the event, ensuring easy access for all interested parties.

Availability of Recorded Rebroadcast

For those unable to attend the live session, Bio-Techne plans to offer a recorded rebroadcast. Interested individuals can listen to the replay by dialing specific numbers and referencing the designated Conference ID for the playback. This recorded session will be available for an extended period of time, allowing ample opportunity for review.

About Bio-Techne Corporation

Bio-Techne Corporation stands at the forefront of global life sciences. The company specializes in providing innovative tools and bioactive reagents that serve the research and clinical diagnostic communities. They play a crucial role in enabling scientific investigations into biological processes and diseases, facilitating drug discovery, and enhancing the accuracy of clinical tests.

Significant Impact on Research and Clinical Diagnostics

Through an extensive portfolio of products, Bio-Techne has achieved remarkable financial milestones, reporting over $1.2 billion in net sales recently. With approximately 3,100 dedicated employees worldwide, they focus on supporting the advancement of science and healthcare by developing high-quality solutions that meet the demands of modern research.

Staying Connected with Bio-Techne

For continuous updates on their innovations and corporate news, Bio-Techne encourages stakeholders to visit their official website or follow them on various social media platforms, including LinkedIn, X, and YouTube. These channels provide valuable insights into their latest developments and contributions to the scientific community.

Frequently Asked Questions

What is the purpose of the conference call hosted by Bio-Techne?

The conference call is intended to discuss Bio-Techne's financial results for the first quarter of fiscal 2026 and share insights with stakeholders.

How can one access the conference call?

Participants can access the call by dialing in using provided phone numbers or joining via the online webcast.

Will there be a recording available for those who cannot attend the live call?

Yes, a recorded rebroadcast will be available after the live conference call, allowing individuals to catch up on the discussion at their convenience.

What is the Conference ID for the call?

The Conference ID for the Bio-Techne conference call is TECHQ1.

What products does Bio-Techne offer?

Bio-Techne offers a wide range of innovative tools and bioactive reagents that assist in scientific research and clinical diagnostics.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.